CVRx (CVRX) to Release Earnings on Thursday

CVRx (NASDAQ:CVRX) is projected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect CVRx to post earnings of ($0.42) per share and revenue of $15.75 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

CVRx Price Performance

NASDAQ CVRX opened at $6.55 on Tuesday. The company has a current ratio of 9.62, a quick ratio of 8.60 and a debt-to-equity ratio of 1.03. The stock’s 50 day moving average is $7.43 and its two-hundred day moving average is $8.15. The company has a market capitalization of $171.68 million, a price-to-earnings ratio of -3.24 and a beta of 1.31. CVRx has a 1-year low of $4.30 and a 1-year high of $15.41.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Canaccord Genuity Group upped their price target on CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CVRx in a research note on Monday, December 29th. Finally, Cantor Fitzgerald increased their target price on shares of CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.40.

Institutional Investors Weigh In On CVRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CVRX. Alliancebernstein L.P. boosted its stake in CVRx by 10.7% in the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after acquiring an additional 1,700 shares during the last quarter. XTX Topco Ltd bought a new position in shares of CVRx in the 2nd quarter worth $155,000. Cresset Asset Management LLC grew its stake in shares of CVRx by 3.5% during the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock worth $315,000 after purchasing an additional 1,823 shares during the period. Wexford Capital LP bought a new stake in CVRx in the third quarter valued at about $372,000. Finally, Bridgeway Capital Management LLC lifted its stake in CVRx by 8.9% in the third quarter. Bridgeway Capital Management LLC now owns 54,000 shares of the company’s stock valued at $436,000 after buying an additional 4,400 shares during the period. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.